The HemOnc Pulse Live at ASH: Robert Orlowski, MD, PhD, on Bispecifics, MRD in Myeloma

By Chadi Nabhan, MD, MBA, FACP, Robert Orlowski, MD, PhD - Last Updated: February 1, 2023

Robert Orlowski, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses advances in myeloma treatment with Chadi Nabhan, MD, MBA, FACP, during the 2022 ASH Annual Meeting. Dr. Orlowski and Dr. Nabhan discussed bispecific antibodies, novel targets, the role of minimal residual disease in clinical practice, and more.

Advertisement

Post Tags:ASH22
Advertisement
Advertisement
Advertisement